Table 1.

Summary of clinicopathologic characteristics of 4,046 patients with invasive breast tumors included in this tissue microarray series

CharacteristicsNo. patients (%)
Age at diagnosis, y
    ≤40380 (9.4)
    40-49767 (19)
    50-651,435 (35.5)
    >651,464 (36.2)
Menstrual status at referral
    Premenopausal1,188 (29.4)
    Postmenopausal2,761 (68.2)
    Pregnant2 (0.1)
    Unknown95 (2.3)
Histology
    Ductal3,661 (90.5)
    Lobular308 (7.6)
    Other77 (1.9)
Grade
    1 (well differentiated)211 (5.2)
    2 (moderately well or partially differentiated)1,582 (39.1)
    3 (poorly differentiated)2,069 (51.1)
    Unknown184 (4.5)
Tumor size, cm
    ≤22,093 (51.7)
    2-51,697 (41.9)
    >5219 (5.4)
    Unknown37 (0.9)
Lymphovascular invasion
    Positive1,750 (43.3)
    Negative2,120 (52.4)
    Unknown176 (4.3)
Percentage of positive/total number of examined axillary lymph nodes (%)
    02,161 (53.4)
    0-25876 (21.7)
    >25825 (20.4)
    Unknown184 (4.5)
Local therapy
    No breast surgery60 (1.5)
    Mastectomy + radiation therapy631 (15.6)
    Mastectomy alone1,557 (38.5)
    Lumpectomy alone135 (3.3)
    Lumpectomy + radiation therapy1,663 (41.1)
Adjuvant systemic therapy (AST)
    None1,689 (41.7)
    Tamoxifen only1,305 (32.3)
    Ovarian ablation or hormone therapy other than tamoxifen7 (0.2)
    Chemotherapy only, AC148 (3.7)
    Chemotherapy AC + tamoxifen125 (3.1)
    Chemotherapy only, CMF429 (10.6)
    Chemotherapy CMF + tamoxifen39 (1)
    Chemotherapy only, FAC92 (2.3)
    Chemotherapy FAC + tamoxifen68 (1.7)
    Chemotherapy only (other)70 (1.7)
    Chemotherapy (other) + tamoxifen69 (1.7)
    Ovarian ablation or hormone therapy + chemotherapy5 (0.1)
  • Abbreviations: AC, doxorubicin and cyclophosphamide; CMF, cyclophosphamide, methotrexate, and fluorouracil; FAC, fluorouracil, doxorubicin, and cyclophosphamide.